Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis

5/1/24 8:33:47 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALRN alert in real time by email

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect

Positive trend was observed in seven of eight IPF biomarkers evaluated

Low-dose LTI-03 was well-tolerated, with no safety signal observed

Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024

Company to host conference call on Wednesday, May 1st at 9:00 am ET

Get the next $ALRN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALRN

Date	Price Target	Rating	Analyst

More analyst ratings

$ALRN
Press Releases

Fastest customizable press release news feed in the world

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent effects in five biomarkers evaluated compared to low dose LTI-03 Data from Cohort 2 of the Phase 1b clinical trial confirms results from Cohort 1, with four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set Planning is underway for a Phase 2 clinical trial AUSTIN, Texas, Nov. 14, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significan
11/14/24 4:15:00 PM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2
11/13/24 7:00:00 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term AUSTIN, Texas, Oct. 12, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the pr
10/12/24 9:00:00 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care

Aileron Therapeutics to be Included in the Russell Microcap® Index
AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S.
7/1/24 8:00:00 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of 2024 AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron", the "Company", "we", "our" or "us") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended Decemb
4/15/24 5:20:25 PM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics Announces CEO Transition
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join th
3/12/24 8:00:00 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a biomarker indicative of epithelial health and lung function decline, suggesting potential therapeutic effect Positive trend observed in seven out of eight IPF biomarkers in Cohort 2, with four biomarkers statistically significant in the combined Cohort 1 and Cohort 2 data set, and dose dependent movement of five biomarkers compared to low dose LTI-03 indicative of active LTI-03 pharmacodynamics High-dose LTI-03 was well-tolerated, with no safety signals observed Planning is underway for a Phase 2
11/13/24 7:00:00 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024 Company to host conference call on Wednesday, May 1st at 9:00 am ET WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ
5/1/24 8:30:23 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endpoint Evaluating cycles 1-6, the imbalance increases further (79% of cycles on ALRN-6924 versus 57% on placebo) Interim finding on the trial's composite primary endpoint, which was the proportion of treatment cycles free of Grade ≥3 neutropenia, anemia, thrombocytopenia, blood transfusions, use of growth factors, dose reductions/delays in the first 4 cycles, demonstrated 56% of cycles on ALRN-6924 ve
6/29/22 6:30:55 AM ET
$ALRN
Biotechnology: Pharmaceutical Preparations
Health Care

Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis

Chat with this insight

Recent Analyst Ratings for $ALRN

$ALRN Press Releases

Fastest customizable press release news feed in the world

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

$ALRN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Aivado Manuel

SEC Form 4 filed by Director Von Rickenbach Josef H

SEC Form 4 filed by Director Fairey William

$ALRN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Windsor James Brian bought $758 worth of shares (225 units at $3.37) (SEC Form 4)

Windsor James Brian bought $9,987 worth of shares (5,076 units at $1.97), increasing direct ownership by 11,035% to 5,122 units (SEC Form 4)

$ALRN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Aileron Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Aileron Therapeutics Inc.

SEC Form SC 13G/A filed by Aileron Therapeutics Inc. (Amendment)

$ALRN SEC Filings

SEC Form 8-K filed by Aileron Therapeutics Inc.

SEC Form 10-Q filed by Aileron Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Aileron Therapeutics Inc.

$ALRN Leadership Updates

Live Leadership Updates

$ALRN Financials

Live finance-specific insights

$ALRN Market Insights

Live Market Insights

Aileron Therapeutics to be Included in the Russell Microcap® Index

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Aileron Therapeutics Announces CEO Transition

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Included In The Russell Microcap Index

Aileron Therapeutics Q1 2024 GAAP EPS $(0.86) Misses $(0.14) Estimate

Aileron Therapeutics shares are trading lower after the company announced the pricing of an underwritten registered direct offering of 4,273,505 shares and accompanying warrants at a combined offering price of $4.68.

Recent Analyst Ratings for
$ALRN

$ALRN
Press Releases

$ALRN
Insider Trading

$ALRN
Insider Purchases

$ALRN
Large Ownership Changes

$ALRN
SEC Filings

$ALRN
Leadership Updates

$ALRN
Financials

$ALRN
Market Insights